Bidirectional association between migraine and fibromyalgia: retrospective cohort analyses of two populations

Penn, I-Wen; Chuang, Eric Y.; Chuang, Tien-Yow; Lin, Cheng‐Li; Kao, Chia‐Hung

doi:10.1136/bmjopen-2018-026581

Cited by 34 publications

(34 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we found no significant association between fibromyalgia and migraine or neuropathic pain. These results rather contradicted findings in the literature [34][35][36]. Akdag Uzun et al concluded that fibromyalgia occurred with greater frequency in patients with migraine, which supported a hypothesis that dopamine might play a role [37].…”

Section: Discussionmentioning

confidence: 87%

Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases

Mathieu

Couderc

Pereira³

et al. 2020

JCM

View full text Add to dashboard Cite

To investigate the physiopathology of pain in chronic inflammatory rheumatic diseases (CIRDs), we assessed the prevalence of migraine and neuropathic pain in 499 patients with CIRDs. We studied 238 patients with rheumatoid arthritis, 188 with spondyloarthritis (SpA), 72 with psoriatic arthritis (PsA), and 1 unclassified. Migraine was diagnosed according to IHS migraine diagnostic criteria. Neuropathic pain was diagnosed when patients scored at least 3 on the DN4 questionnaire. Participants completed a validated self-assessment questionnaire. Migraine prevalence was 34% (165/484), and it was highest in PsA. Risk factors for migraine were a high level of anxiety, female sex, young age, and TNF-alpha inhibitor treatment (OR = 1.90 (1.13–3.25)). Besides, high disease activity was a risk factor in SpA. Blood CRP level was not significantly associated with migraine. Of 493 patients with CIRDs, 21.5% had chronic pain with neuropathic characteristics. Compared to the French general population, these patients had significantly higher prevalences of migraine (two-fold) and neuropathic pain (three-fold). This study showed that migraine and neuropathic pain frequently occurred in patients with rheumatic diseases. Therefore, upon reporting residual pain, these patients should be checked for the presence of migraine or neuropathic pain, despite adequate clinical control of rheumatic disease.

show abstract

Section: Discussionmentioning

confidence: 87%

Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases

Mathieu

Couderc

Pereira³

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Several studies have reported a high prevalence (up to 80%) of FM in patients with CM (9,10,13,14), and there is a large body of evidence that central sensitization comprises the common pathophysiologic basis (1). FM and migraine when present together contribute to increased disability.…”

Section: Discussionmentioning

confidence: 99%

“…CM is a prevalent and disabling neurologic disorder that is often associated with comorbid conditions that can influence both its prognosis and its impact on quality of life ( 1 , 3 , 23 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia

Real

Terán

2020

Front. Neurol.

View full text Add to dashboard Cite

Introduction: Fibromyalgia (FM) is a frequent comorbidity in patients with chronic migraine (CM). PREEMPT trials, which demonstrated the efficacy of OnabotulinumtoxinA (OnabotA) on CM, excluded patients with FM. Our aim was to evaluate the effectiveness of OnabotA in a series of patients with CM and FM. Methods: We analyzed patients with a previous diagnosis of CM and FM who had received sessions of OnabotA quarterly between January 2014 and January 2020 in a specialized Headache Clinic. Primary endpoint was the reduction in moderate to severe headache days at 3, 6, 9, and 12 months. Results: Data were collected from 31 patients with CM and FM that received OnabotA (100% females). Mean age at first procedure was 50.2 ± 11.3 years. Depression (93.5%), other central sensitization syndromes (irritable bowel syndrome, interstitial cystitis, multiple chemical sensitivity, endometriosis, and chronic fatigue syndrome) (48.4%), and medication overuse headache (90.3%) were frequent comorbidities. 48.4% of patients had failed ≥3 preventives previously. The percentage of patients who achieved ≥30 and ≥50% moderate-severe headache reduction on the third month was 65.4 and 48.2%, respectively. Twenty-three patients completed four cycles of treatment, with 13.4 fewer headache days per month than at baseline (p < 0.001). By 1 year, 69.5% had ≥50% reduction of headache frequency and 39.1% had a ≥75% reduction. In 4 cases (21%), OnabotA was interrupted due to a lack of response. Only mild adverse effects were recorded. Conclusion: OnabotA is an effective treatment for CM in patients with FM.

show abstract

“…Norepinephrine and serotonin inhibit central excitability, but low norepinephrine and serotonin levels were noted in patients with depression. Serotonin deficiency increases painful sensation in chronic pain [ 26 ], and low norepinephrine was noted in migraine [ 27 ]. Migraine with psychological syndrome increases symptom severity and requires hospital treatment.…”

Section: Discussionmentioning

confidence: 99%

Turbinate Submucosal Reduction Operation Reduced Migraine Admission among Patients with Chronic Hypertrophic Rhinitis

Cheng

Chang

Cheng

et al. 2020

IJERPH

View full text Add to dashboard Cite

Rhinitis increases migraine risk. Chronic hypertrophic rhinitis can be treated with turbinate submucosal reduction operation. The relationship between migraine and chronic hypertrophic rhinitis after turbinate submucosal reduction operation is still unclear. The goal of this study was to evaluate the correlation between turbinate submucosal reduction operation and subsequent migraine admission in Asian chronic hypertrophic rhinitis patients. We identified patients suffering from chronic hypertrophic rhinitis and receiving turbinate submucosal reduction operation. The control group was selected from patients with chronic hypertrophic rhinitis without operation. The event was migraine admission. The risk factors of migraine admission were established using multivariate Cox proportional hazard regression. The risk of migraine admission after turbinate submucosal reduction operation is represented by a hazard ratio (HR) of 0.858 (95% confidence interval (CI): 0.633–0.962). The higher risk of migraine included depression with HR 4.348 (95% CI: 2.826–6.69), anxiety with HR 3.75 (95% CI: 2.267–6.203), fibromyalgia with HR of 7.326 (95% CI: 3.427–15.661), and asthma with HR 1.969 (95% CI: 1.11–3.491). Our study revealed that turbinate submucosal reduction operation led to a 14.2% reduction in migraine admission. Clinicians should understand the benefit of turbinate submucosal reduction operation and provide suitable treatments for comorbid conditions. Further prospective studies are required to confirm our findings.

show abstract

Bidirectional association between migraine and fibromyalgia: retrospective cohort analyses of two populations

Cited by 34 publications

References 50 publications

Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases

Prevalence of Migraine and Neuropathic Pain in Rheumatic Diseases

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia

Turbinate Submucosal Reduction Operation Reduced Migraine Admission among Patients with Chronic Hypertrophic Rhinitis

Contact Info

Product

Resources

About